Cardiovascular & Hematological Disorders-Drug Targets

(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Editor-in-Chief

Garry X. Shen
University of Manitoba
Winnipeg, MB
(Canada)

Back

Become EABM
Become Reviewer



Meet Our Editorial Board Member free to download

Volume:18   Issue: 2
Pp: 81-82
Gjumrakch Aliev
DOI: 10.2174/1871529X1802180628114324



Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs free to download

Volume:18   Issue: 2
Pp: 83-85
Konstantinos P. Imprialos, Konstantinos Stavropoulos* and Michael Doumas
DOI: 10.2174/1871529X1802180628114731



Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions

Volume:18   Issue: 2
Pp: 86-93
Panteleimon Pantelidis*, Andreas Kalliakmanis, Christos Mitas, Michail Sideris, Charalampos Grassos, Andreas Pittaras and Athanasios Manolis
DOI: 10.2174/1871529X18666180206130218




Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents

Volume:18   Issue: 2
Pp: 94-103
Konstantinos Avranas*, Konstantinos Imprialos, Konstantinos Stavropoulos, Georgios Lales, Alexandos Manafis, Anastasia Skalkou and Lars Kihm
DOI: 10.2174/1871529X18666180206160838




Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs

Volume:18   Issue: 2
Pp: 104-113
Konstantinos P. Imprialos*, Konstantinos Stavropoulos, Nikiforos Stavropoulos, Dimitrios Patoulias, Konstantinos Petidis, Charalampos Grassos, Kyriakos Dimitriadis and Constantinos Tsioufis
DOI: 10.2174/1871529X18666180206144342




Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits

Volume:18   Issue: 2
Pp: 114-119
Dragan Lovic*, Andreas Pittaras, Manolis Kallistratos, Constantinos Tsioufis, Charalampos Grassos, Dragan Djordjevic, Ivan Tasic and Athanasios Manolis
DOI: 10.2174/1871529X18666180227102137




Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease

Volume:18   Issue: 2
Pp: 120-126
Konstantinos Stavropoulos*, Konstantinos P. Imprialos, Nikiforos Stavropoulos, Sofia Bouloukou, Georgios Kerpiniotis, Kyriakos Dimitriadis, Constantinos Tsioufis and Michael Doumas
DOI: 10.2174/1871529X18666180206155349




Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure

Volume:18   Issue: 2
Pp: 127-133
Vasilios Papademetriou* and Eleni Geladari
DOI: 10.2174/1871529X18666180405102658




Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke

Volume:18   Issue: 2
Pp: 134-138
Dimitrios Milonas and Konstantinos Tziomalos*
DOI: 10.2174/1871529X18666180206120444




Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice

Volume:18   Issue: 2
Pp: 139-146
Dimitrios Patoulias*, Alexandros Manafis, Christos Mitas, Konstantinos Avranas, Georgios Lales, Ioanna Zografou, Christos Sambanis and Asterios Karagiannis
DOI: 10.2174/1871529X18666180206123149




What Genetics Tells us about Cardiovascular Disease in Diabetic Patients?

Volume:18   Issue: 2
Pp: 147-152
Habib Haybar, Mohammad Taha Jalali and Zeinab Deris Zayeri*
DOI: 10.2174/1871529X18666180212114305




Platelet Activation Polymorphisms in Ischemia

Volume:18   Issue: 2
Pp: 153-161
Habib Haybar, Elahe Khodadi, Kazem Zibara and Najmaldin Saki*
DOI: 10.2174/1871529X18666180326121239




A Rare Case of Tricuspid Valve Endocarditis Caused by Enterococcus Gallinarum in a Patient with Recurrent Urinary Tract Infection

Volume:18   Issue: 2
Pp: 162-164
Tsipis Angelos*, Skandalakis Nikolaos, Kanakakis Nikolaos, Pilatis Nektarios and Petropoulou Evdokia
DOI: 10.2174/1871529X18666180302113428